Literature DB >> 10588951

Preparation of a stable fresh frozen primary lipoprotein[a] (Lp[a]) standard.

G M Kostner1, A Ibovnik, H Holzer, H Grillhofer.   

Abstract

LP[a] is one of the most atherogenic lipoproteins consisting of an LDL-like core particle and a covalently linked glycoprotein of variable size. Due to its structural features, its heterogeneity and instability, there are great difficulties in standardizing quantitative immunochemical Lp[a] assays. One particular problem is the preparation of a pure primary standard, which is sufficiently stable to be used for value assignment of secondary reference material. Here we describe a method to purify Lp[a] to virtual homogeneity. When mixed with glycerol at a ratio of 1:1, the preparation is stable in the deep frozen state for more than 12 months. This latter material gave dose;-response curves in several immunochemical assays that were parallel to fresh or frozen sera, freshly prepared Lp[a], and other proposed reference materials. After determination of the protein content by amino acid analysis, it was possible to assign concentrations in molar and mass units to these preparations considering the theoretical molecular weights of the particular apo[a] isoform. Thus we propose to use this procedure for preparation of a "gold standard" for Lp[a] assays.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10588951

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  7 in total

1.  Galactose-specific asialoglycoprotein receptor is involved in lipoprotein (a) catabolism.

Authors:  Andelko Hrzenjak; Sasa Frank; Xingde Wo; Yonggang Zhou; Theo Van Berkel; Gert M Kostner
Journal:  Biochem J       Date:  2003-12-15       Impact factor: 3.857

2.  Farnesoid X receptor represses hepatic human APOA gene expression.

Authors:  Indumathi Chennamsetty; Thierry Claudel; Karam M Kostner; Anna Baghdasaryan; Dagmar Kratky; Sanja Levak-Frank; Sasa Frank; Frank J Gonzalez; Michael Trauner; Gert M Kostner
Journal:  J Clin Invest       Date:  2011-08-01       Impact factor: 14.808

3.  Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice.

Authors:  Indumathi Chennamsetty; Karam M Kostner; Thierry Claudel; Manjula Vinod; Sasa Frank; Thomas S Weiss; Michael Trauner; Gerhard M Kostner
Journal:  J Lipid Res       Date:  2012-08-28       Impact factor: 5.922

4.  Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events.

Authors:  Beate R Jaeger; Yvonne Richter; Dorothea Nagel; Franz Heigl; Anja Vogt; Eberhard Roeseler; Klaus Parhofer; Wolfgang Ramlow; Michael Koch; Gerd Utermann; Carlos A Labarrere; Dietrich Seidel
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2009-03

5.  Analysis of cholesterol levels in lipoprotein(a) with anion-exchange chromatography.

Authors:  Yuji Hirowatari; Hiroshi Yoshida; Hideo Kurosawa; Yuko Shimura; Hidekatsu Yanai; Norio Tada
Journal:  J Lipid Res       Date:  2009-10-30       Impact factor: 5.922

Review 6.  Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations.

Authors:  Nishant P Shah; Neha J Pajidipati; Robert W McGarrah; Ann Marie Navar; Sreekanth Vemulapalli; Michael A Blazing; Svati H Shah; Adrian F Hernandez; Manesh R Patel
Journal:  Am J Cardiol       Date:  2020-04-07       Impact factor: 2.778

7.  A new type of non-Ca2+-buffering Apo(a)-based fluorescent indicator for intraluminal Ca2+ in the endoplasmic reticulum.

Authors:  Karin Osibow; Roland Malli; Gerhard M Kostner; Wolfgang F Graier
Journal:  J Biol Chem       Date:  2005-12-20       Impact factor: 5.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.